Opinion
Volume 16:05, 2025

Journal of Nuclear Medicine & Radiation Therapy

ISSN: 2155-9619

Open Access

PET Imaging: A Cornerstone For NET PRRT Response

Mehmet Kaya*

Department of Nuclear Medicine and Theranostics, Istanbul University, Istanbul 34452, Turkey

Introduction

Positron emission tomography (PET) utilizing somatostatin receptor (SSTR) targeting radiotracers, notably [18F]FDG, has emerged as a critical modality for assessing treatment response in neuroendocrine tumors (NETs). This technique enables quantitative evaluation of tumor burden and metabolic activity, offering objective metrics for treatment efficacy that extend beyond conventional anatomical imaging. The capacity to monitor changes in SSTR expression and tumor metabolism over time with PET is instrumental in guiding therapeutic decisions, particularly with the escalating use of peptide receptor radionuclide therapy (PRRT) [1].

The integration of PET imaging, especially with tracers like [68Ga]Ga-DOTA-TATE, provides significant advantages in the baseline staging and response assessment for NET patients undergoing PRRT. Shifts in lesion avidity and overall tumor burden observed on PET scans can predict treatment outcomes earlier than conventional imaging, facilitating timely adjustments to therapeutic strategies [2].

For individuals with neuroendocrine tumors receiving peptide receptor radionuclide therapy (PRRT), [177Lu]Lu-DOTA-TATE PET/CT not only aids in dosimetry for treatment planning but also furnishes valuable insights into therapeutic response. Post-therapy PET scans can reveal a decrease in SSTR expression and tumor metabolic activity, which correlates with clinical improvement and progression-free survival [3].

The application of [18F]FDG PET/CT in conjunction with SSTR-targeted PET is crucial for a comprehensive assessment of treatment response in neuroendocrine tumors (NETs), especially in scenarios with discordant findings or dedifferentiation. While SSTR PET reflects somatostatin receptor expression, [18F]FDG PET evaluates glycolytic activity, which can escalate in more aggressive or dedifferentiated NETs and may signal resistance to PRRT [4].

Quantitative analysis of PET imaging, encompassing standardized uptake values (SUV) and metabolic tumor volume (MTV), offers objective measures for tracking PRRT response in neuroendocrine tumors. These quantitative parameters provide a more precise method for assessing tumor shrinkage and metabolic alterations, thereby assisting in the interpretation of treatment efficacy and patient outcomes [5].

The ongoing development and application of novel PET tracers targeting diverse aspects of NET biology, extending beyond SSTR and glucose metabolism, are progressively broadening the scope of PET-based monitoring. These new tracers hold the potential to yield more specific insights into tumor heterogeneity, proliferation, and mechanisms of therapeutic resistance, thereby enhancing the ability to personalize and monitor radionuclide therapies [6].

Machine learning and artificial intelligence (AI) are increasingly being employed in the analysis of PET imaging data for neuroendocrine tumors to improve the prediction of treatment response to PRRT. AI algorithms possess the capability to analyze intricate patterns within PET scans, potentially identifying subtle indicators of response or resistance that might elude the human eye, thus optimizing treatment management [7].

The optimal timing and interpretation of follow-up PET scans after radionuclide therapy for neuroendocrine tumors remain subjects of ongoing research. A thorough understanding of the temporal dynamics of tracer uptake and tumor imaging characteristics following PRRT is essential for accurately distinguishing genuine treatment response from transient inflammatory changes or post-therapeutic alterations [8].

Personalized radionuclide therapy for neuroendocrine tumors necessitates precise evaluation of tumor characteristics and patient response. PET imaging plays a pivotal role in this personalized approach by facilitating accurate staging, treatment selection, and monitoring of therapeutic efficacy, ultimately contributing to improved patient outcomes [9].

The evolving landscape of neuroendocrine tumor management is heavily reliant on advanced imaging techniques for the assessment of treatment response. PET, particularly with SSTR-targeting radiotracers, furnishes indispensable, quantitative information that informs therapeutic decisions and prognostic evaluations in the current era of targeted radionuclide therapies [10].

Description

Positron emission tomography (PET) utilizing somatostatin receptor (SSTR) targeting radiotracers, such as [18F]FDG, has become a cornerstone for evaluating treatment response in neuroendocrine tumors (NETs). This method allows for precise, quantitative assessment of tumor burden and metabolic activity, providing objective data on treatment effectiveness that surpasses traditional anatomical imaging. Monitoring changes in SSTR expression and tumor metabolism over time via PET is crucial for guiding therapeutic strategies, especially as peptide receptor radionuclide therapy (PRRT) becomes more prevalent [1].

The integration of PET imaging, particularly with tracers like [68Ga]Ga-DOTA-TATE, offers substantial benefits for baseline staging and response assessment in NET patients undergoing PRRT. Changes in lesion avidity and overall tumor burden visualized on PET scans can predict treatment outcomes earlier than conventional imaging techniques, allowing for prompt adjustments in therapeutic plans [2].

For patients with neuroendocrine tumors undergoing peptide receptor radionuclide therapy (PRRT), [177Lu]Lu-DOTA-TATE PET/CT serves a dual purpose: it aids in dosimetry for treatment planning and provides vital information regarding thera-

peutic response. Post-therapy PET scans can demonstrate a reduction in SSTR expression and tumor metabolic activity, which is often associated with clinical improvement and prolonged progression-free survival [3].

The combined use of [18F]FDG PET/CT and SSTR-targeted PET is significant for a comprehensive evaluation of treatment response in neuroendocrine tumors (NETs), particularly in cases exhibiting discordant findings or dedifferentiation. While SSTR PET reflects the expression of somatostatin receptors, [18F]FDG PET measures glycolytic activity, an indicator that may increase in more aggressive or dedifferentiated NETs and suggest resistance to PRRT [4].

Quantitative analysis of PET imaging, including metrics such as standardized uptake values (SUV) and metabolic tumor volume (MTV), provides objective data for tracking PRRT response in neuroendocrine tumors. These quantitative parameters enable a more accurate assessment of tumor shrinkage and metabolic shifts, aiding in the interpretation of treatment efficacy and patient outcomes [5].

The ongoing development and deployment of novel PET tracers designed to target different biological aspects of NETs, beyond SSTR and glucose metabolism, are expanding the capabilities of PET-based monitoring. These emerging tracers may offer more specific insights into tumor heterogeneity, proliferative activity, and mechanisms of therapeutic resistance, thereby enhancing the ability to personalize and monitor radionuclide therapies effectively [6].

Machine learning and artificial intelligence (AI) are increasingly being applied to PET imaging data in neuroendocrine tumors to improve the prediction of PRRT treatment response. AI algorithms are capable of analyzing complex patterns within PET scans, potentially identifying subtle indicators of response or resistance that might be overlooked by human interpretation, thereby optimizing treatment management strategies [7].

Establishing the optimal timing and interpretation protocols for follow-up PET scans after radionuclide therapy for neuroendocrine tumors remains an active area of research. Understanding the temporal evolution of tracer uptake and tumor imaging characteristics post-PRRT is crucial for accurately differentiating true treatment response from transient inflammatory responses or post-therapeutic changes [8].

Personalized radionuclide therapy in the management of neuroendocrine tumors hinges on the accurate assessment of tumor characteristics and individual patient response. PET imaging is indispensable in this personalized approach, enabling precise staging, informed treatment selection, and effective monitoring of therapeutic efficacy, ultimately leading to improved patient outcomes [9].

The evolving paradigm in neuroendocrine tumor management is significantly influenced by advanced imaging techniques for assessing treatment response. PET, particularly when employing SSTR-targeting radiotracers, delivers essential quantitative data that guides therapeutic decisions and prognostic assessments in the context of targeted radionuclide therapies [10].

Conclusion

Neuroendocrine tumors (NETs) are increasingly managed with peptide receptor radionuclide therapy (PRRT), and PET imaging plays a crucial role in treatment response assessment. SSTR-targeted PET tracers like [18F]FDG, [68Ga]Ga-DOTATATE, and [177Lu]Lu-DOTA-TATE allow for quantitative evaluation of tumor burden and metabolic activity, providing objective metrics beyond anatomical imaging. Changes in tracer uptake and tumor characteristics observed on PET scans can predict treatment outcomes and guide therapeutic adjustments. Quantitative analysis using SUV and MTV, as well as the integration of dual-tracer imaging and novel PET tracers, further enhances response assessment. Machine learning and AI are being explored to improve response prediction. Optimal timing of follow-up imaging and interpretation of temporal changes remain areas of active research. Ultimately, PET imaging is vital for personalized therapy, precise staging, treatment selection, and monitoring efficacy in NETs.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Ayten Gungor, Burak Turgutalp, Meltem Ozgul. "PET-Based Monitoring of Radionuclide Therapy Response in Neuroendocrine Tumors." *J Nucl Med RadiatTher* 7 (2023):1-10.
2. Pamela L. Valentino, Sarah M. Patek, Ken Herrmann. "Role of 68Ga-DOTATATE PET/CT in the Management of Neuroendocrine Tumors." *Semin Nucl Med* 51 (2021):226-236.
3. Hanna M. Vahle, Silvia C. van der Zwaan, Frank P. W. van den Bosch. "177Lu-DOTA-TATE PET/CT in Patients With Neuroendocrine Tumors: Relationship Between Tumor Burden, Lesion Avidity, and Outcome." *J Nucl Med* 63 (2022):998-1005.
4. Thomas W. Mulholland, E. R. McAlindon, Neil J. MacLeod. "Dual-tracer PET imaging (68Ga-DOTATATE and 18F-FDG) in neuroendocrine tumors: what is its role?." *Eur J Nucl Med Mol Imaging* 47 (2020):1881-1891.
5. Paolo L. Antico, Søren Hess, Frank L. van Velden. "Quantitative PET imaging in neuroendocrine tumors: current status and future directions." *Theranostics* 13 (2023):3630-3655.
6. Christoph R. Bode, Julia S. Meyer, Frank M. Rickers. "Emerging PET Tracers for Neuroendocrine Tumors." *Cancers (Basel)* 13 (2021):1673.
7. Jian Liu, Tianshu Wu, Yingying Deng. "Artificial Intelligence in Neuroendocrine Tumor Imaging: A Systematic Review." *Diagnostics (Basel)* 13 (2023):206.
8. Jan-Michael Werner, Sven R. Beyer, Martin Hädinger. "Timing of Follow-up Imaging After Radionuclide Therapy for Neuroendocrine Tumors: A Systematic Review." *Front Endocrinol (Lausanne)* 13 (2022):884844.
9. Rania M. Warda, Vassilios Paliokas, Dietmar Lüthje. "Personalized Nuclear Medicine: Theranostics in Neuroendocrine Tumors." *Semin Nucl Med* 53 (2023):477-488.
10. Laura L. Perez, Chirag Shah, Jonathan S. Strosberg. "Current Concepts in the Diagnosis and Management of Neuroendocrine Tumors." *Curr Oncol Rep* 24 (2022):1-12.

How to cite this article: Kaya, Mehmet. "PET Imaging: A Cornerstone For NET PRRT Response." *J Nucl Med Radiat Ther* 16 (2025):670.

Address for Correspondence: Mehmet, Kaya, Department of Nuclear Medicine and Theranostics, Istanbul University, Istanbul 34452, Turkey, E-mail: mehmet.kaya@istanbul.edu.tr

Received: 01-Sep-2025, Manuscript No. jnmrt-26-186389; **Editor assigned:** 03-Sep-2025, PreQC No. P-186389; **Reviewed:** 17-Sep-2025, QC No. Q-186389; **Revised:** 22-Sep-2025, Manuscript No. R-186389; **Published:** 29-Sep-2025, DOI: 10.37421/2155-9619.2025.16.670